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Abstract
wWe reported previously T. Horie, Y. Mizushina, M. Takemura, F. Sugawara, A. Matsukage, S. Yoshida, K. Sakaguchi,
 . x X  .Int. J. Mol. Med., 1 1998 83–90. that a 5 -monophosphate form breMP of bredinin, which has been used clinically as an
 .  .immunosuppressive drug, selectively suppressed the activities of mammalian DNA polymerase a pol. a and b pol. b .
In a preliminary study of the action mode, for pol. b , breMP acted by competing with, unexpectedly, not only the substrate
but also with the template-primer. The mode might be attributable to the structure and function of pol. b itself. We
therefore investigated the biochemical inhibition mode of pol. b in more detail by using two pol. b fragments which were
proteolytically separated into the template-primer-binding domain and the catalytic domain. BreMP inhibited only the
catalytic activity of the catalytic domain fragment, and could not bind to the template-primer-binding domain fragment,
suggesting that it directly competes with the substrate at its binding site of the catalytic domain, and indirectly, but
simultaneously and competitively disturbs the template-primer incorporation into the template-primer-binding domain.
q 1998 Elsevier Science B.V. All rights reserved.
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Bredinin 4-carbamoyl-1-b-D-ribofuranosylimida-
. zolium-5-olate is a derivative of AICA-riboside 5-
.aminoimidazole-4-carboxamide ribonucleoside , and
w xa potent cytotoxic agent for lymphocytes 1 . Bre-
dinin has been used clinically as an immunosuppres-
w xsive drug in Japan 2–4 , although its molecular
action mode is unclear.
w xWe previously found 5 that bredinin was rapidly
converted to a 5X-monophosphate form of bredinin
) Corresponding author. Fax: q81-471-23-9767; E-mail:
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 .breMP in vivo, and that breMP selectively sup-
pressed the activities of mammalian DNA poly-
 .  .merase a pol. a and b pol. b to almost the
same extent, whereas bredinin itself had no such
effect. Such an agent which strongly inhibits the
activity of pol. b in vivo had not been reported
w x  .previously 5 . DideoxyTTP ddTTP , a potent pol. b
inhibitor, suppresses the activity of pol. b in vitro to
the same extent as does breMP, but ddTTP cannot
penetrate into cells as breMP can. The inhibitory
effect of breMP on pol. a was stronger than that
w xshown by aphidicolin 5 . As is well known, pol. a is
a replicative polymerase which is abundant only in
proliferating cells, and pol. b is probably necessary
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w xfor DNA repair and recombination 6 . Pol. b is
expressed and distributed mostly in the thymus and
the testes, in which the endogenous DNA recombina-
w xtion process occurs 7 . We therefore concluded that
the inhibitions of pol. a and b may influence the
proliferation of B cells and DNA recombination in
w xthe process of T cell formation, respectively 5 .
w xIn preliminary studies 5 , we observed an unusual
biochemical response by DNA polymerase b to
breMP. For pol. a , breMP acted by competing only
with the substrate, and non-competitively with the
w xtemplate-primer 5 . For pol. b , in contrast, breMP
acted by competing with not only the nucleotide
w xsubstrate but also with the template-primer 5 , al-
though the binding sites for the substrate and tem-
w xplate-primer on pol. b differ 8 . We therefore con-
cluded that breMP interacted with or affected both of
the binding sites on pol. b , thereby decreasing its
affinity for the DNA template and substrate, whereas
it competes with the substrate binding site on pol. a
w x5 . The unexpected response by pol. b is thought to
be directly related to the structure and function of
pol. b itself.
The purpose of the present study was to further
investigate the action mode of breMP on pol. b , and
to determine how the inhibition mode of breMP on
pol. b is competitive against both template-primer
DNA and the nucleotide substrate. As the binding
targets, we used monomeric recombinant rat pol. b
with the M.W. 39 kDa and the two distinct domains
w xdescribed by Kumar et al. 8,9 , i.e., the N-terminal
 .‘template binding’ domain 8 kDa and the C-termi-
 .nal ‘catalytic’ domain 31 kDa .
Bredinin and breMP were isolated and synthesized
in the Research Laboratories of Asahi Chemical In-
 .dustry Tokyo, Japan by the method described by
w xShuto et al. 10 . Rat pol. b and the pol. b fragments
of the 8 kDa domain and 31 kDa domain were
prepared by the method described by Kumar et al.
w x9 . The standard DNA polymerase assay, the gel
mobility shift assay and the in vitro DNA synthesis
 .  .on poly dA roligo dT were also described previ-
w xously 11,12 .
Table 1 shows the results of the kinetic analysis of
 .breMP. In the kinetic analysis, when poly dC roligo
 .dG and dGTP were the DNA template-primer12 –18
and substrate, respectively, the inhibition of pol. b
by breMP was competitive with both the DNA tem-
 .plate and the substrate Table 1 . There was no
 .change in the apparent V 52 pmolrh for themax
DNA template, while the K for the DNA templatem
increased from 1.0 to 9.6 mM template DNA in the
presence of zero to 20 mM breMP. Similarly, the
apparent V for the substrate dTTP was unchangedmax
at 120 pmolrh, whereas a 4-fold increase in the Km
was observed in the presence of 60 mM breMP. The
 .IC value was 20 mM. The inhibition constant K50 i
value, obtained from Dixon plots, was found to be 6
mM for the DNA template and 36 mM for the
substrate dTTP. Since the K value for the DNAi
template was about six times higher than that for the
substrate, the affinity of breMP to pol. b might be
higher at the DNA template-binding site than at the
substrate-binding site. Since breMP is a derivative of
authentic nucleotides, and since it bears a structural
w xresemblance to guanosine monophosphate 1 , one
might speculate that the structure of pol. b is more
acceptable to incorporate the breMP molecule than
the DNA template-primer which does not contain
guanosine monophosphate, and than substrates other
than dGTP. The data in Table 1 preclude this possi-
bility, however, because the K values, the ICi 50
value, the K values and the V values werem max
almost unchanged when the substrate and the DNA
 .template-primer were dTTP and poly dA roligo
 .dT , respectively. When the DNA template-12 –18
primer was activated DNA, although the values of the
IC slightly increased, the K , the K and the V50 i m max
were essentially stable. BreMP does not necessarily
work as an inhibitor analogous to guanine-nucleotide.
It competes with either the substrate or template-
primer, it may bind to both sites, and subsequently
inhibits the catalytic activity. Biochemically, this
mode of action is an unusual phenomenon.
Fig. 1A shows the dose-curves of the inhibition of
pol. b by breMP under the presence of a non-ionic
 .detergent 0.05% Nonidet P40, NP-40 , bovine serum
 .  .  .  .albumin BSA 80 mgrml or poly rC 40 mM .
The inhibition by breMP was not reversed by the
addition of NP-40 to the reaction mixture, indicating
that breMP bound tightly to the enzyme protein Fig.
.  .1A . BSA and poly rC also had little or no influence
on the inhibitory effect of breMP, suggesting that the
effect of the breMP did not result from the non-
specific adhesion of breMP to the enzymes, but rather
the binding to DNA polymerases occurs selectively
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Table 1
X  .  .Kinetic analysis of the 5 -monophosphate form breMP of bredinin inhibition of DNA polymerase b 0.05 units
Template DNA IC Ki BreMP concentration K V Inhibitory50 m max
 .  .  .  .  .or substrate mM mM mM mM pmolrh mode
 .  .Poly dA roligo dT 4 0 1.0 56 Competitive12 –18
5 1.7
10 6.7
17 20 10
3w xH dTTP 39 0 4.0 125 Competitive
20 5.6
40 9.3
60 16
 .  .Poly dC roligo dT 6 0 1.0 52 Competitive12 –18
5 1.6
10 6.2
20 20 9.6
3w xH dTTP 36 0 4.0 120 Competitive
20 5.4
40 8.9
60 16
Activated DNA 11 0 1.0 54 Competitive
5 1.5
10 5.8
30 20 9.1
3w xH dTTP, dATP, dCTP, dGTP 33 0 4.0 122 Competitive
20 5.2
40 8.2
60 15
 .The inhibition mode was obtained from a Lineweaver–Burk plot. The inhibition constant K was obtained from a Dixon plot.i
 .Fig. 1A . Fig. 1B indicates the dose-curves of the
inhibition of pol. b by breMP after the enzyme was
 .preincubated with the substrate dTTP or the tem-
  .  ..plate-primer poly dA roligo dT at 378C for 30
min. After the preincubation, the standard reaction
 .  .mixture without dTTP or poly dA roligo dT was
added to the enzyme solution with breMP, and then
incubated at 378C for 30 min. Only when the enzyme
was preincubated with dTTP, breMP significantly
 .lost the inhibitory activity Fig. 1B . The preincuba-
tion with the template-primer rather strengthened the
 .inhibitory effect by breMP Fig. 1B . This result may
indicate that breMP acts directly by competing with
the substrate on pol. b , and the template-primer
competes indirectly with breMP. This suggestion is
not in harmony with the Table 1 data suggesting that
the affinity of breMP might be higher at the DNA
template-binding site than at the substrate-binding
site.
To solve the question of why breMP seems to
compete with both the DNA template and the sub-
strate, its binding should be precisely analyzed in
relation to the protein structure of pol. b. Fortu-
nately, the rat pol. b used in this study has been
extensively studied, including its amino acid se-
quence and its secondary and tertiary structures
w x8,9,13–17 . The pol. b used in this study is a single
polypeptide of 39 kDa, and is composed of four
individual subdomain fragments, the 8 kDa domain,
w x 190 192fingers, palm, and thumb 17 . The Asp and Asp
relate to the substrate-binding site, and Asp256 is an
amino acid which has a key role in the DNA-tem-
w xplate binding site 14–17 . The enzyme can be di-
vided into two domain fragments of 8 kDa and 31
w xkDa polypeptides using controlled proteolysis 9 : an
8 kDa N-terminal fragment and a 31 kDa C-terminal
fragment. The 31 kDa domain contains three domains
other than the 8 kDa domain, and is the catalytic part
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Fig. 1. Effect of various reaction conditions and preincubation
conditions on the inhibition of DNA polymerase b activity 0.05
.  .  .  .  .units by breMP. A 80 mgrml BSA v , 40 mM poly rC ’
 .  .or Nonidet P-40 0.05% l was added to the reaction mixture
of pol. b. The reaction mixture without any additions is indicated
 .  .  .by the symbol B. B The enzyme pol. b , the substrate dTTP
 .  .and the inhibitor breMP I , the enzyme, the template DNA
  .  .  ..  .poly dA roligo dT s2r1 and the inhibitor ^ or the12-18
 .enzyme and the inhibitor ‘ were preincubated at 378C for 30
min.
involved in DNA polymerization. The 8 kDa domain
w xis the DNA template-primer-binding domain 8 . We
prepared the whole enzyme of pol. b with a molecu-
 .lar weight M.W. of 39 kDa, and two domain frag-
ments of the 8 kDa and 31 kDa polypeptides. Both
fragments were obtained by the controlled proteolysis
w xdescribed by Kumar et al. 9 , and purified through
FPLC Superose 12 chromatography to near homo-
w w xxgeneity see Fig. 4 in Ref. 11 . The template-
primer-binding protein activity and the DNA poly-
merization activity were analyzed by a gel mobility
shift assay and by analyzing the products of
 .  .poly dA -oligo dT used as the template-primer, re-16
spectively.
Fig. 2 shows the gel mobility shift assay of the
 .M13 DNA-39 kDa pol. b binding complex lane 5
and M13 DNA-8 kDa domain fragment binding com-
 .plex lane 10 . The 39 kDa pol. b and 8 kDa domain
fragment were bound to M13 DNA and were shifted
in the gel, but the 31 kDa fragment, the catalytic
domain without a DNA-binding site, was not shifted
w w xxsee Fig. 5A in Ref. 11 . In the binding, M13 DNA
 .at 2.2 nmol nucleotide was added with 0.2 nmol of
the enzyme or the fragment. The M13 DNA used was
often separated into a major band and a faint band
 .lanes 1 and 6 in Fig. 2 . The molecular ratios of the
 .breMP and the enzyme or the fragment are shown
 .as the inhibitor and enzyme ratio IrE in Fig. 2.
The IrE ratios for 39 kDa pol. b in lanes 2, 3 and 5
were 50, five and zero, respectively, and similarly,
those for the 8 kDa domain fragment, shown in lanes
 .7, 8 and 10, were also 50, five and zero Fig. 2 . The
 .positive control used for the strongest interference ,
 . w xfomitellic acid A FA-A described previously 12 ,
 .gave an IrE ratio of five lanes 4 and 9 in Fig. 2 .
BreMP did not interfere with the complex formation
 .between M13 DNA and pol. b lane 2 in Fig. 2 or
between M13 DNA and the 8 kDa fragment lane 7
.in Fig. 2 . Even an excess amount of breMP did not
interfere with the binding between M13 DNA and the
 . enzyme or the 8 kDa fragment lanes 3 and 8 in
.Fig. 2 . BreMP competed with the DNA template,
but it could not bind to its site, suggesting that the
competition is a secondary phenomenon.
The question thus arose as to whether breMP has a
direct influence on the catalytic site. We tested
whether the catalytic activity on the 31 kDa domain
fragment is inhibited by breMP. Although the cat-
 .alytic domain fragment 31 kDa protein is basically
the substrate-binding site, it can weakly bind to the
DNA template-primer, and polymerize the DNA
w x  .  .8,11,12 . We used poly dA -oligo dT as the tem-16
plate-primer, and analyzed newly synthesized DNA
 .fragments produced by the 31 kDa protein Fig. 3 .
The reaction products in vitro were investigated by
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 .Fig. 2. Gel mobility shift analysis. Gel shift analysis of binding between M13 DNA and pol. b. M13 DNA 2.2 nmol; nucleotide mixed
 .with purified proteins and breMP. Lanes 2–5 contained purified pol. b 39 kDa at a concentration of 0.2 nmol; lanes 7–10 contained
purified 8 kDa fragment at a concentration of 0.2 nmol; lanes 1 and 6 contained no enzyme. Lanes 1 and 6, lanes 2 and 7, lanes 3 and 8
and lanes 5 and 12 were each mixed with breMP: 0, 10, 1, or 0 nmol, respectively. Lanes 4 and 9 were mixed with 1 nmol fomitellic acid
 .A FA-A . Samples were run on a 1.2% agarose gel in 0.1 M Tris–acetate, pH 8.3 containing 5 mM EDTA at 50 V for 2 h. A photograph
of an ethidium bromide-stained gel is shown.
using denaturing polyacrylamide gel electrophoresis.
In the experiment shown in Fig. 3, 20 ng of pol. b
was used, resulting in the re-initiation of nascent
chains during the synthesis period. Fig. 3 shows the
 .products formed by the enzyme lanes 1 to 6 or the
 .31 kDa domain fragment lanes 7 to 12 . It is known
w xthat pol. b is a distributive enzyme 18 , which adds
a single nucleotide and then dissociates from the
template-product complex, and the 31 kDa fragment
can replicate DNA, as does the whole enzyme. Within
a 10-min incubation period, most of the primers were
 .elongated lane 6 in Fig. 3 . With 40 ng of the 31
kDa fragment, DNA replication was also observed
 .lane 12 in Fig. 3 . The 8 kDa domain fragment was
wincapable of replicating DNA see Fig. 6A in Ref.
w xx11 . At an IrE ratio of more than 5, breMP com-
pletely suppressed the DNA polymerization by the
whole enzyme and the 31 kDa domain fragment. The
action of the 39 kDa enzyme was interfered with in
almost the same manner as was the 31 kDa fragment.
When the IrE ratio for the enzyme was 0.5, the
DNA synthesis was gradually suppressed. These re-
sults suggest that a few molecules, perhaps one
molecule, of breMP compete with one molecule of
the substrate deoxyribonucleotide, bind to the sub-
strate-binding site on the 31 kDa domain fragment,
and subsequently interfere with the polymerization.
The structures of the substrate-binding site may be
more acceptable to incorporate the breMP molecule
than the authentic nucleotides.
We concluded that the inhibition process, based on
the present results, is as follows: Since the DNA-tem-
plate binding site on the 8 kDa domain fragment sit
in front of the substrate binding site on the 31 kDa
fragment composed of three subdomains, i.e., the
w xfingers, the palm, and the thumb 14–17 , initially
one breMP molecule becomes inserted into the crevice
between the template-primer-binding site on the 8
kDa domain and the catalytic site on the 31 kDa
domain, and then, as does ddTTP, breMP binds
competitively to the hydrophilic portion of the sub-
strate-binding site on the 31 kDa domain. The breMP
bound to the catalytic site indirectly, but immediately
and competitively, interferes with the incorporation
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 .  .Fig. 3. Analysis of the poly dA roligo dT templaterprimer synthesis products. DNA synthesis reactions were carried out with 20 mM
 .  .  . w 32 x  .of poly dA roligo dT s2r1 and 20 mM of a- P dTTP 60 Cirmmol , and the products were examined by gel electrophoresis16
 .and imaging analysis as described in the text. The enzyme concentrations were as follows: lanes 1–6, 20 ng 0.51 pmol of the 39 kDa
 .intact pol. b ; lanes 7–12, 40 ng 1.29 pmol of the 31 kDa fragment. The breMP concentrations were as follows: lanes 1–12 were 5.10,
2.55, 1.02, 0.51, 0.26, 0, 12.9, 6.45, 2.58, 1.29, 0.65 and 0 pmol, respectively. Markers indicate the positions of the extended primer.
of the DNA template-primer on the 8 kDa domain
fragment, the other bank of the crevice.
We previously reported results of kinetic analyses
of several pol. b-inhibitors such as long-chain fatty
w x w xacids 11,19 , new triterpenoids 12,20 and liposac-
w xcharides 21,22 . All of these agents also outwardly
acted by competing with both the DNA template and
the substrate, and were substances which directly
bound to the 8 kDa domain fragment by competing
w xwith the DNA template 19,20 . The action of breMP
differed from these pol. b inhibitors, and was similar
to that of ddTTP. These findings indicate that for pol.
b , both breMP and ddTTP seemed to be competitive
with either the substrate or the DNA-template.
Bredinin itself does not inhibit the activity of pol.
b , and after being converted to its 5X-monophosphate
 .form breMP in vivo, breMP does so in a mode
similar to that of ddTTP. The present results showed
that breMP is a substance similar to a cell-permeable
ddTTP. DdTTP cannot penetrate into viable cells.
Since such a compound influencing pol. b activity
and penetrating into viable cells has never been re-
ported before, and since there are many tissues in
which a replication polymerase such as the a-type
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does not function, breMP could be a key agent for
analyzing the in vivo functions of pol. b in these
w xtissues. We speculated previously 5 that some of the
immunosuppressive nucleoside derivatives, including
bredinin, might be inhibitors of the DNA poly-
merases involved in DNA repair and recombination,
especially the b-type, because they might be related
 .to immunological V D J recombination. Screening
such ddTTP-like agents may reveal new clinically
immunosuppressive drugs. In this light, it is interest-
ing that breMP may be a ddTTP-like agent inhibiting
pol. b activity.
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